Streetbeat News

Regulatory

NBTX

Nanobiotix has announced updated preliminary results from its Phase 1 pancreatic cancer trial and new exploratory analysis from its completed Phase 1 head and neck cancer trial. The ongoing Phase 1 study of NBTXR3 in locally advanced pancreatic cancer established a favorable safety profile and recommended dose. An exploratory analysis of completed Study 102 showed a positive correlation between Objective Response to RT-activated NBTXR3 and the extension of Overall Survival for elderly, frail patients with head and neck cancer.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 7:01 am

BTCUSD

ETHUSD

Former President Donald Trump's Ethereum (ETH) holdings have increased by $91,000 since he launched his NFT collection in December 2022, reaching a total of $2.7 million. The increase in value is attributed to the recent surge in cryptocurrency prices, fueled by renewed hopes for SEC ETF approval and market optimism following the dismissal of charges against two Ripple executives in the XRP lawsuit.

Portfolio Pulse from Mehab Qureshi

October 23, 2023 | 6:49 am

REGN

SNY

Regeneron Pharmaceuticals and Sanofi have announced sustained efficacy of Dupixent (dupilumab) Phase 3 results in children aged 1 to 11 with Eosinophilic Esophagitis for up to one year. The data presented at ACG 2023 showed maintained histologic and endoscopic improvements with no new safety signals. The sBLA for Dupixent to treat children with EoE is under Priority Review in the U.S. If approved, Dupixent would be the first and only FDA-approved treatment for these children.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 6:23 am

BTCUSD

ETHUSD

MSTR

XRPUSD

MicroStrategy Inc's Bitcoin holdings have become profitable again as Bitcoin's value climbed above $30,000, driven by renewed hopes for SEC ETF approval and market optimism following the dismissal of charges against two Ripple executives. The company's total Bitcoin holdings were acquired at an average price of approximately $29,582 per coin, resulting in a profit of roughly $17.82 million. However, data suggests that if MicroStrategy had invested in Ethereum instead, their profit would have been significantly higher.

Portfolio Pulse from Mehab Qureshi

October 23, 2023 | 3:35 am

IMMP

New data on the first line treatment of metastatic non-small cell lung cancer was presented at ESMO 2023. The data was part of the TACTI-002 Webcast Presentation by Immutep Limited (IMMP).

Portfolio Pulse from Charles Gross

October 22, 2023 | 10:48 pm

BAC

GSK

MA

Several entities including Bank of America (BAC), Mastercard (MA), the NRA, GlaxoSmithKline (GSK), and others are lobbying for cannabis banking reform under the Secure and Fair Enforcement Regulation (SAFER) Banking Act. The Act aims to provide legal cannabis businesses access to banks and financial institutions. The Act has passed in the Senate Banking Committee and is expected to move to the full Senate and then to the House.

Portfolio Pulse from Maureen Meehan

October 22, 2023 | 6:21 pm

EXEL

Exelixis, Inc. (NASDAQ:EXEL) announced results from a phase 3 trial of cabozantinib, which showed significant improvements in progression-free survival for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. The company plans to discuss these results with the U.S. Food and Drug Administration.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:56 pm

ALPMY

SGEN

Seagen Inc. and Astellas Pharma Inc. announced positive results from the Phase 3 EV-302 clinical trial for PADCEV in combination with KEYTRUDA versus chemotherapy. The combination improved overall survival and progression-free survival in patients with previously untreated locally advanced or metastatic urothelial cancer. The risk of death was reduced by 53% and overall survival improved by more than 15 months compared to chemotherapy. These results will form the basis of global regulatory submissions.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:48 pm

AMGN

Amgen (NASDAQ:AMGN) announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS in combination with Vectibix. Both doses demonstrated a statistically significant superiority in progression-free survival over the investigator's choice of therapy in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The results were presented at the ESMO 2023 Congress and published in the New England Journal of Medicine.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:44 pm

MRK

Merck (NYSE:MRK) announced results from the Phase 3 KEYNOTE-A39 trial, conducted in collaboration with Seagen and Astellas, evaluating KEYTRUDA plus Padcev. The combination significantly prolonged overall survival by 53% compared to chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma. The results were selected for presentation at the European Society for Medical Oncology Congress 2023.

Portfolio Pulse from Charles Gross

October 22, 2023 | 2:42 pm